Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"
04-13 Aptamer Sciences Inc announced that it has received KRW 30.00043989 billion in funding from Alticast Corporation, Daihyun Eng & Const Co., Ltd., K&P Investment Co., Ltd., Vision 2 Co., Ltd., JDK Partners Co., Ltd. and other investors. CI
04-08 Aptamer Sciences Inc announced that it has received KRW 12 billion in funding CI
03-24 Aptamer Sciences Inc agreed to acquire Choolip Inc. from Wellnew & Co for $11.4 million. CI
02-12 Aptamer Sciences Inc announced that it has received KRW 7 billion in funding CI
02-09 FOCUS AI Co., Ltd. announced that it has received KRW 5.423916904 billion in funding from Aptamer Sciences Inc, Nex Plan Co., Ltd., 3S E&D Co., Ltd. CI
01-27 Aptamer Sciences Inc announced that it expects to receive KRW 12 billion in funding CI
01-25 FOCUS AI Co., Ltd. announced that it has received KRW 999.999944 million in funding from Aptamer Sciences Inc CI
01-15 Aptamer Sciences Inc announced that it expects to receive KRW 7 billion in funding from Bellum Fund 1 CI
12-18 FOCUS AI Co., Ltd. announced that it expects to receive KRW 999.999944 million in funding from Aptamer Sciences Inc CI
12-02 FOCUS AI Co., Ltd. announced that it expects to receive KRW 9.42391668 billion in funding from Aptamer Sciences Inc and other investors CI
25-10-23 Alticast Corporation completed the acquisition of 8.07% stake in Aptamer Sciences Inc from Han Dong-il, Ryu Seong-ho, Jang Seung-gi. CI
25-09-07 Alticast Corporation agreed to acquire an 8.07% stake in Aptamer Sciences Inc from Han Dong-il, Ryu Seong-ho, Jang Seung-gi for KRW 4.4 billion. CI
25-08-20 Aptamer Sciences wins 320 million won order RE
1 day-0.47%
Current month-14.57%
1 month-34.16%
3 months-42.72%
6 months+11.84%
Current year+12.14%
1 week 824
Extreme 824
991
1 month 721
Extreme 721
1,315
Current year 675
Extreme 675
1,998
1 year 675
Extreme 675
1,998
3 years 675
Extreme 675
5,320
5 years 675
Extreme 675
14,000
10 years 675
Extreme 675
19,175
Manager TitleAgeSince
Chief Executive Officer 53 2025-10-26
Director of Finance/CFO 56 2025-10-26
Chief Tech/Sci/R&D Officer 53 -
Director TitleAgeSince
Director/Board Member 53 2025-10-26
Director/Board Member 56 2025-10-26
Director/Board Member 51 2025-10-26
Change 5-day change 1-year change 3-year change Capi.($)
-0.47%0.00%-24.78%-83.81% 34.55M
-0.22%-1.14%-11.88%-13.09% 43.51B
+0.76%+9.42%+303.09%+540.82% 33.29B
-0.47%-0.35%+3.38%+31.20% 29.34B
-4.74%-6.31%+10.75%-20.99% 29.9B
+0.06%+4.36%+13.31%+21.11% 25.42B
-0.02%+10.18% - - 14.36B
-0.98%-1.86%+53.43%+106.06% 13.18B
-0.29%-4.40%+3.13%+1.69% 12.72B
+1.67%+1.35%+105.56%+81.16% 12.08B
Average -0.47%+1.21%+50.67%+73.79% 21.38B
Weighted average by Cap. -0.63%+1.76%+61.91%+103.55%
Logo Aptamer Sciences Inc
Aptamer Sciences Inc is a Korea-based company principally engaged in the research and development of bio therapeutic drugs. The Company provides services include aptamer synthesis and aptamer discovery. The Company also develops biopharmaceuticals such as insulin substitutes, insulin sensitizers, and liver cancer drugs. In addition, the Company also produces lung cancer diagnostic kits.
Employees
-
Date Price Change Volume
26-06-17 850.00 -0.47% 38,347
26-06-16 854.00 +0.35% 59,635
26-06-15 851.00 +0.35% 113,849
26-06-12 848.00 -2.53% 167,058
26-06-11 870.00 +2.35% 37,579
  1. Stock Market
  2. Stocks
  3. A291650 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!